Montreal, Canada, June 15th, 2017. BioAmber Inc. (NYSE: BIOA, TSX: BIOA) is pleased to announce the launch of BIO-SA™ pharmaceutical grade. This new grade of material provides a USP/NF and FCC Grade of bio-succinic acid manufactured under the United States Food and Drug Administration’s (FDA) good manufacturing practices (GMP) for food and Excipients. The United States Pharmacopeia (USP), the National Formulary (NF), and the Food Chemicals Codex (FCC) are the public pharmacopeia standards for medicines, food ingredients, dietary supplement products, and ingredients.
These standards are used by regulatory agencies and manufacturers to ensure products are of the appropriate identity, strength, quality, purity and consistency.
“Having met the stringent requirements contained in the NF and FCC reflects BioAmber’s continued dedication to quality through our best-in-class production and purification processes. By achieving this new benchmark, our global customers in the food, pharmaceutical and dietary supplement industries can be assured BioAmber’s facility adheres to the rigorous quality control standards set by the United States Food and Drug Administration (FDA).” said Fabrice Orecchioni, BioAmber’s President & COO. “This grade will allow BioAmber to supply these high-value industries with commercial volumes of an FDA regulated bio-succinic acid, a grade previously unavailable to these markets before today”, he added.
BioAmber (NYSE: BIOA, TSX: BIOA) is a renewable materials company. Its innovative technology platform combines biotechnology and catalysis to convert renewable feedstock into building block materials that are used in a wide variety of everyday products including plastics, paints, textiles, food additives and personal care products. For more information visit www.bio-amber.com
This press release contains forward-looking statements, which are subject to substantial risks, uncertainties and assumptions. These statements often include words such as “believe,” “expect,” “anticipate,” “intend,” “plan,” “estimate,” “seek,” “will,” “may” or similar expressions. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the events and circumstances reflected in the forward-looking statements will be achieved or occur and the timing of events and circumstances and actual results could differ materially from those projected in the forward- looking statements. Accordingly, you should not place undue reliance on these forward-looking statements. All such statements speak only as of the date made, and we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise. For additional disclosure regarding these and other risks faced by BioAmber, see disclosures contained in BioAmber’s public filings with the SEC including, the “Risk Factors” section of BioAmber’s most recent Annual Report on Form 10-K and the recent quarterly report on Form 10-Q.
BioAmber Investor Contact
Sr. VP Business Development
Tel (514) 844 8000 ext 260